2023
Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
Greene S, Velazquez E, Anstrom K, Clare R, DeWald T, Psotka M, Ambrosy A, Stevens G, Rommel J, Alexy T, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Eisenstein E, Mentz R, Investigators O. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. Circulation 2023, 148: 124-134. PMID: 37212600, PMCID: PMC10524905, DOI: 10.1161/circulationaha.123.064842.Peer-Reviewed Original ResearchMeSH KeywordsFurosemideHeart FailureHumansQuality of LifeSodium Potassium Chloride Symporter InhibitorsStroke VolumeTorsemideConceptsPatient Health Questionnaire-2Prespecified secondary end pointsQuality of lifeEffects of torsemideSecondary end pointsHeart failurePatient-reported outcomesKansas City Cardiomyopathy Questionnaire clinical summary scoreNew York Heart Association classPatient Health Questionnaire-2 scoreEnd pointQuestionnaire-2Loop diuretic agentsLoop diuretic useProportion of patientsBaseline health statusClinical summary scoreEjection fraction phenotypeSignificant differencesDiuretic strategyTorsemide groupCause hospitalizationCause mortalityDiuretic usePrimary therapy
2019
Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study
Butler J, Greene SJ, Shah SH, Shah SJ, Anstrom KJ, Kim RJ, Kalogeropoulos AP, Velazquez EJ, Hernandez AF, Desvigne-Nickens P, Scherzer R, Hsue PY, Braunwald E. Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. Journal Of Cardiac Failure 2019, 26: 371-380. PMID: 31682908, PMCID: PMC7195219, DOI: 10.1016/j.cardfail.2019.10.011.Peer-Reviewed Original ResearchConceptsDiastolic dysfunctionBody mass indexAntiretroviral therapyN-terminal pro-B-type natriuretic peptide levelsPro-B-type natriuretic peptide levelsHuman immunodeficiency virus-infected individualsCross-sectional case-control studyLow-density lipoprotein levelsHigher body mass indexHigh-sensitivity troponin IHIV RNA copiesSignificant valvular diseaseNatriuretic peptide levelsHigher interleukin-6Normal ejection fractionVirus-infected individualsLeft atrial sizePersistent atrial fibrillationProgressive cardiac remodelingSymptom frequency scoreAntiretroviral Therapy studyCardiac magnetic resonanceCase-control studyCarboxyl-terminal telopeptideCD4 countBurden of medical co‐morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy
Ambrosy AP, Stevens SR, Al‐Khalidi H, Rouleau JL, Bouabdallaoui N, Carson PE, Adlbrecht C, Cleland JGF, Dabrowski R, Golba KS, Pina IL, Sueta CA, Roy A, Sopko G, Bonow RO, Velazquez EJ, Investigators O. Burden of medical co‐morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. European Journal Of Heart Failure 2019, 21: 373-381. PMID: 30698316, PMCID: PMC6818499, DOI: 10.1002/ejhf.1404.Peer-Reviewed Original ResearchConceptsCharlson co-morbidity indexCCI scoreSurgical revascularizationEjection fractionMedical therapySTICH trialHeart failureIschemic cardiomyopathyKansas City Cardiomyopathy QuestionnaireCo-morbidity indexCoronary artery bypassCo-morbid conditionsHealth-related qualityCoronary artery diseaseRisk of deathProportional hazards modelYears of ageTreatment effectsGreater functional limitationsArtery bypassCause mortalityIschemic etiologyArtery diseaseWalk testBaseline confounders
2017
Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial
DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK, Lin G, Redfield MM, Lewis G, Semigran MJ, Anstrom KJ, Hernandez AF, Velazquez EJ. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. European Journal Of Heart Failure 2017, 19: 893-900. PMID: 28194841, PMCID: PMC5511088, DOI: 10.1002/ejhf.754.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersDouble-Blind MethodEchocardiographyExercise ToleranceFemaleFollow-Up StudiesHeart Failure, SystolicHeart VentriclesHumansMaleMiddle AgedMyocardial ContractionNatriuretic Peptide, BrainOxygen ConsumptionPeptide FragmentsProcollagenQuality of LifeRetrospective StudiesStroke VolumeTime FactorsVentricular Function, LeftConceptsLV global longitudinal strainGlobal longitudinal strainImpaired LV global longitudinal strainVentricular global longitudinal strainEjection fractionQuality of lifeRELAX trialExercise capacityHeart failureN-terminal pro-brain natriuretic peptideLeft ventricular global longitudinal strainWorse LV global longitudinal strainLog-transformed NT-proBNPPro-brain natriuretic peptideNormal LV ejection fractionLongitudinal strainHeart failure scoreLV ejection fractionPeak oxygen consumptionHFpEF patientsMinnesota LivingDiastolic dysfunctionNT-proBNPSystolic dysfunctionClinical characteristics
2016
Associations between positive emotional well-being and stress-induced myocardial ischemia Well-being scores predict exercise-induced ischemia
Feigal JP, Boyle SH, Samad Z, Velazquez EJ, Wilson JL, Becker RC, Williams RB, Kuhn CM, Ortel TL, Rogers JG, O'Connor CM, Jiang W. Associations between positive emotional well-being and stress-induced myocardial ischemia Well-being scores predict exercise-induced ischemia. Journal Of Psychosomatic Research 2016, 93: 14-18. PMID: 28107887, PMCID: PMC6044283, DOI: 10.1016/j.jpsychores.2016.11.012.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionHealth-related behaviorsMyocardial ischemiaStable ischemic heart disease patientsIschemic heart disease patientsWall motion score indexExercise-induced ischemiaTreadmill exercise testingEpidemiologic Studies Depression ScaleStress-induced ischemiaInverse correlationHeart disease patientsSignificant inverse correlationInducible ischemiaAdult patientsExercise testingIschemic responseEjection fractionDisease patientsTreatment trialsSimilar inverse correlationDepression ScaleExercise stressDepressive symptomsUnderscore areas
2015
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction
Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. New England Journal Of Medicine 2015, 373: 2314-2324. PMID: 26549714, PMCID: PMC4712067, DOI: 10.1056/nejmoa1510774.Peer-Reviewed Original ResearchConceptsHeart failureEjection fractionIsosorbide mononitratePlacebo groupDose regimensWalk distanceLife scoresN-terminal pro-brain natriuretic peptidePro-brain natriuretic peptideEnd pointSignificant between-group differencesIsosorbide mononitrate groupLow daily activityNT-proBNP levelsPrimary end pointSecondary end pointsSubmaximal exercise capacityDose-escalation regimenHours of activityActivity levelsBetween-group differencesDaily activity levelsDaily activitiesActivity toleranceExercise capacity
2014
Quality-of-life outcomes with coronary artery bypass graft surgery in ischemic left ventricular dysfunction: a randomized trial.
Mark DB, Knight JD, Velazquez EJ, Wasilewski J, Howlett JG, Smith PK, Spertus JA, Rajda M, Yadav R, Hamman BL, Malinowski M, Naik A, Rankin G, Harding TM, Drew LA, Desvigne-Nickens P, Anstrom KJ. Quality-of-life outcomes with coronary artery bypass graft surgery in ischemic left ventricular dysfunction: a randomized trial. Annals Of Internal Medicine 2014, 161: 392-9. PMID: 25222386, PMCID: PMC4182862, DOI: 10.7326/m13-1380.Peer-Reviewed Original ResearchConceptsIschemic left ventricular dysfunctionLeft ventricular dysfunctionCoronary artery diseaseMedical therapyVentricular dysfunctionSTICH trialArtery diseaseKansas City Cardiomyopathy Questionnaire overall summary scoreCoronary artery bypass graft surgeryGuideline-based medical therapyKansas City Cardiomyopathy QuestionnaireMultivessel coronary artery diseaseRoutine coronary artery bypassSymptomatic high-risk patientsArtery bypass graft surgeryLeft ventricular ejection fractionPrespecified secondary end pointsLife outcomesTreatment-related qualityBypass graft surgeryCoronary artery bypassMedical therapy groupSecondary end pointsHigh-risk patientsVentricular ejection fractionImpact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction A VALIANT Study (Valsartan In Acute Myocardial Infarction)
Lewis EF, Li Y, Pfeffer MA, Solomon SD, Weinfurt KP, Velazquez EJ, Califf RM, Rouleau JL, Kober L, White HD, Schulman KA, Reed SD. Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction A VALIANT Study (Valsartan In Acute Myocardial Infarction). JACC Heart Failure 2014, 2: 159-165. PMID: 24720924, DOI: 10.1016/j.jchf.2013.12.003.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBundle-Branch BlockCaptoprilDeath, Sudden, CardiacDrug Therapy, CombinationFemaleHealth StatusHeart FailureHospitalizationHumansMaleMyocardial InfarctionQuality of LifeRecurrenceStrokeSurvivorsTetrazolesTreatment OutcomeValineValsartanConceptsNonfatal CV eventsEQ-5D assessmentCV eventsVisual analog scaleEQ-5D scoresCardiovascular eventsMyocardial infarctionEQ-5DBaseline EQ-5D scoresKillip class IINonfatal cardiovascular eventsHealth-related qualityLinear mixed-effects regression modelsQuality of lifeMixed effects regression modelsVALIANT studyWorse HRQLVAS scoresEjection fractionNonfatal eventsMI survivorsAnalog scaleVALIANT trialGeneric instrumentsPatientsPROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial
Douglas PS, Hoffmann U, Lee KL, Mark DB, Al-Khalidi HR, Anstrom K, Dolor RJ, Kosinski A, Krucoff MW, Mudrick DW, Patel MR, Picard MH, Udelson JE, Velazquez EJ, Cooper L, investigators P. PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial. American Heart Journal 2014, 167: 796-803.e1. PMID: 24890527, PMCID: PMC4044617, DOI: 10.1016/j.ahj.2014.03.003.Peer-Reviewed Original ResearchConceptsCoronary artery diseasePROMISE trialAnatomical testingProspective Multicenter Imaging StudyDiagnostic strategiesInitial diagnostic strategyMajor procedural complicationsSubsequent care decisionsComposite of deathPrimary end pointLarge pragmatic trialClinical care teamQuality of lifeDiagnostic testing strategiesMultidetector coronaryChest painSymptomatic patientsUnstable anginaArtery diseaseProcedural complicationsRandomized trialsSymptomatic subjectsClinical effectivenessMyocardial infarctionPragmatic trial
2013
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Givertz MM, Mann DL, Lee KL, Ibarra JC, Velazquez EJ, Hernandez AF, Mascette AM, Braunwald E. Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients. Circulation Heart Failure 2013, 6: 862-868. PMID: 23861505, PMCID: PMC3902033, DOI: 10.1161/circheartfailure.113.000394.Peer-Reviewed Original Research
2009
Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: Results from the Surgical Treatment for Ischemic Heart Failure trial
Mark DB, Knight JD, Velazquez EJ, Howlett JG, Spertus JA, Djokovic LT, Harding TM, Rankin GR, Drew LA, Szygula-Jurkiewicz B, Adlbrecht C, Anstrom KJ, Investigators F. Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: Results from the Surgical Treatment for Ischemic Heart Failure trial. American Heart Journal 2009, 157: 837-844.e3. PMID: 19376309, PMCID: PMC2694042, DOI: 10.1016/j.ahj.2009.03.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCoronary Artery BypassFemaleFollow-Up StudiesHealth Care CostsHeart FailureHeart VentriclesHumansMaleMiddle AgedMyocardial IschemiaPlastic Surgery ProceduresQuality of LifeRetrospective StudiesStroke VolumeSurveys and QuestionnairesTreatment OutcomeUnited StatesVentricular Function, LeftConceptsCoronary artery bypass graft surgerySurgical ventricular reconstructionIschemic heart failureQuality of lifeHeart failureVentricular reconstructionQOL measuresIschemic Heart Failure (STICH) trialKansas City Cardiomyopathy QuestionnaireTotal index hospitalization costsArtery bypass graft surgeryLeft ventricular ejection fractionBetter QOLIndex hospitalization costsBypass graft surgeryHeart failure symptomsHeart Failure TrialVentricular ejection fractionLeft ventricular functionHealth care costsTreatment-related differencesGraft surgeryEjection fractionSurgical treatmentVentricular function
2005
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, Investigators F. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). American Heart Journal 2005, 150: 323-329. PMID: 16086938, DOI: 10.1016/j.ahj.2004.08.037.Peer-Reviewed Original ResearchMeSH KeywordsAmbulatory CareAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilDrug CostsGlobal HealthHealth Care CostsHealth ResourcesHeart FailureHospital CostsHospitalizationHumansMyocardial InfarctionProspective StudiesQuality of LifeTetrazolesValineValsartanVentricular Dysfunction, LeftConceptsQuality of lifeMyocardial infarctionAcute Myocardial Infarction trialLower medication costsMyocardial Infarction trialHealth-related qualityLinear mixed-effects regression analysisMultinational clinical trialsMixed-effects regression analysisCaptopril groupStudy medicationCardiovascular morbidityVentricular dysfunctionMost patientsHeart failureACE inhibitorsMedication costsProspective economic evaluationClinical trialsHigh riskPatientsValsartanResource useCaptoprilSignificant differences